DALLAS, Feb. 8, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Delcath Systems Inc. (Nasdaq:DCTH). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/DCTH
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Delcath Systems Inc. (DCTH) is a development-stage company that has developed a device designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body. The Company focused its efforts on the development of a single product, the Delcath PHP System, for the treatment of tumors of the liver.
Message Board Search for DCTH: http://www.boardcentral.com/boards/DCTH
In the report, the analyst notes:
"DCTH, a medical technology company testing its proprietary treatment system for metastatic cancers to the liver, announced last week that sufficient events have been reached to allow data analysis to begin on its phase III trial. The trial uses the drug melphalan to treat patients with metastatic melanoma in the liver.
"'We remain very optimistic that the phase III trial will achieve a successful endpoint," Eamonn P. Hobbs, president and CEO of Delcath stated in the press release. "Assuming a successful trial endpoint, we remain committed to filing our NDA with the FDA in April.
"The study's primary objective was to demonstrate a statistically significant improvement in the hepatic progression free survival (HPFS) of patients with metastatic melanoma (ocular or cutaneous) to the liver treated with the Delcath PHP System™ versus patients in the control arm. Secondary endpoints include response rate, duration of response and overall survival."
To read the entire report visit: http://www.investorsoup.com/lp/DCTH
See what investors say about DCTH at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither InvestorSoup nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.